3.1 Sex differences in generalizability of HFrEF trials 109 Supplementary Table 3. Target doses of medication achieved between males and females, stratified by RCT population, RCT-eligible registry population, and RCT-ineligible population. RCT RCT-eligible RCT-ineligible Females Males Females Males Females Males Medications (% of target dose) ACEI OR ARB 0% 11.1% 10.5% 1.1% 0.8% 37.4% 26.8% >0 - <25% 9.5% 8.4% 9.1% 7.2% 7.7% 8.2% 25- <50% 24.7% 24.3% 24.5% 20.4% 18.0% 18.6% 50- <100% 34.2% 36.0% 31.1% 30.3% 19.2% 21.9% ≥100% 20.5% 20.8% 34.2% 41.2% 17.7% 24.5% MRA 0% 60.5% 66.8% 61.6% 60.2% 66.1% 67.3% >0 - <25% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 25- <50% 0.4% 0.2% 30.5% 32.9% 24.0% 24.8% 50- <100% 3.5% 3.7% 3.7% 3.5% 3.5% 3.6% ≥100% 35.6% 29.3% 4.1% 3.4% 6.4% 4.2% Beta-blocker 0% 12.7% 13.6% 0.1% 0.1% 28.5% 25.1% >0 - <25% 16.4% 14.9% 10.2% 8.6% 9.6% 8.5% 25- <50% 28.2% 28.9% 28.4% 26.6% 22.4% 22.3% 50- <100% 27.1% 27.5% 35.6% 36.7% 24.7% 27.1% ≥100% 15.6% 15.1% 25.7% 28.0% 80.6% 17.1% Medications (% of target dose) ACEI OR ARB 0 - <50% 45.3% 43.2% 34.6% 28.4% 63.1% 53.6% ≥50% - ≥100% 54.7% 56.8% 65.4% 71.6% 36.9% 46.4% MRA 0 - <50% 60.9% 67.0% 92.1% 93.2% 90.2% 92.2% ≥50% - ≥100% 39.1% 33.0% 7.9% 6.8% 9.8% 7.8% Beta-blocker 0 - <50% 57.3% 57.4% 38.7% 35.3% 60.5% 55.9% ≥50% - ≥100% 42.7% 42.6% 61.3% 64.7% 105.3% 44.1% All values are statistically significant P<.01 between males and females for the RCT, RCT-eligible, and RCT-ineligible populations
RkJQdWJsaXNoZXIy MjY0ODMw